About Transdermal Drug Delivery
Transdermal drug delivery is a large and growing vertical market of the Pharmaceutical industry. Transdermal drug delivery is defined as a system that utilizes skin as a site for continuous drug administration into the systemic circulation. Several methods of transdermal drug delivery include plasters, various ointments and, most commonly, patches. Transdermal drug administration has several advantages. First, the method of delivery is non-invasive, which is much less traumatic to the patient as compared to other forms of drug delivery. Also, it can be effective in assuring that a patient receives a full dosage of a drug and helps in increasing the compliance rate. However, there are difficulties associated with administering medication through the skin. The natural function of the skin is to act as a protective barrier, so it is often the case that drugs are not chemically suitable to penetrating the skin.
TechNavio's analysts forecast the Global Transdermal Drug Delivery market will grow at a CAGR of 9.92 percent over the period 2014-2018.
MY NOTE: These reports are never 100% accurate, but in general it forecasts that the market will be around 150% of what it is today by 2018. It names Antares as a key vendor in the sector.
You're an idiot. Only an idiot brags about losing 10% wikle holding a stock for 3 years. This stock will see an easy 50% increase from here in a short period of time and yet you say you are not buying? As I said, you are an idiot.
I want to thank all who sold to me. Buying this here at 50% of the 200 DMA with a 19.33 RSI and 17.6 million shares short with 12.4 Days to cover and 50% under the 200 DMA is a no-brainer. The last of the idiots just sold. Thanks again!
Thanks in Advance.
First, I want to thank everyone who sold to me today. I bought a boatload of shares at $4.74 & $4.75. Thank you! To see Max Pain google positionplkays max pain calculator. BTW-Yellen is an absolute idiot. Anyone who listens to that moron gets what they deserve.
That is all in my figures. The settlement with the states (which is also in my figures) can be structured and placed as a lien on future sales of property and dispursed in escrows as things sell. My estimates are extremely conservative at $4.84 a share. Even if you want to assume thge worst and say this will never sell at .7 times reduced sales (remember I have already triple-discounted sales in my calculations) and you say it would only fetch half that or .35 times triple-discounted sales (which would be an ultra-extreme low price), COCO would still be worth $2.42 a share or more than 11 times what it is trading for today!
I am now reducing contingencies and settlements by $50 million (remember teach out went to only 5% also) The company is now worth $4.84 a share.
Remember thatb I said $50-60 million overall and California would be around $5-6 million. Glaxo just settled with 41 states and California over similar accusations. COCO has 20 states so will be half or less since Glaxo is megacorporation with very deep pockets.Here's the June 2014 settlement: GlaxoSmithKline Plc (GSK), the U.K.’s largest drugmaker, will pay $105 million to settle claims by California, New York and more than 40 other states that it illegally promoted asthma and antidepressant drugs.
The accord announced today prohibits Glaxo from providing incentive payments to salespeople that encourage uses of the drugs not indicated on their labels, and from using paid doctors to promote its products. The agreement covers the asthma drug Advair and two antidepressants, Paxil and Wellbutrin.
California’s portion of the settlement, the largest of any state, is $7.1 million, Kamala Harris, the state’s attorney general, said in a statement. Legal documents describing the agreement will be filed today in state court in San Diego, according to Harris.
Glaxo said on May 27 that it faces a criminal probe in the U.K. following allegations in China that its employees bribed doctors, hospitals and medical associations to boost sales. Accusations of wrongdoing by company employees also have surfaced in Iraq, Poland, Jordan and Lebanon. The U.S. Justice Department began looking in 2010 into whether Glaxo and other drugmakers violated a federal law against bribing officials in foreign countries.
Sorry to tell you that you are dead wrong. Thgis isn't some regulatory agency - It's the California Superior Court. They can only use current law and rule on evidence of violations to the law.. The AG has no evidence
They are not going BK - They issued 8k about having to do a reverse split in December to remain on Nasdaq. They have assetrs worth much more than liabilities.
She was hoping to have COCO frozen and forced into a compromised position where they would have to settle on her terms. Now that she has lost, she cannot afford to lose at the next court hearing and must settle on COCO's terms because there is little evidence of any wrongdoing since terms like relevant employment are not defined in any regulations or code. It really is extremely hard to prove COCO has done false advertising without hard figures and the AG has none. Remember that it is the AG's job to prove that COCO has violated the law, and not COCO's job to prove anything. That's why this case will now never go to court. (and why California settled in 2007). I expect they have already started settlement talks after Friday's defeat and a settlement could be announced at any moment for an amount near what COCO settled for in 2007, in the $5-6 million range with no admission of wrongdoing. We should see a nice jump in the stock when it is announced. That's why COCO win in court on Friday was immediately followed by another negative article planted by hedge funds and/or Safalow to help gather shares. Don't forget that there are 28,716,738 shares they now must cover before the announcement. Don't give them yours!
Safalow's company, PAA research put their clients into a COCO short position. It's impossible to say whether a Hedge Fund placed that New York Times article or Safalow placed it for them but it's obvious to anyone with a brain that the reason that the New York times used an obscure person like him for quotes and comments is that he made himself available (or his PR agent did). In other words he contacted them! Otherwise they would never have found him. Here is what he says on his webpage that his company is all about: Absolute Return Focus – We are strict followers of the mantra that “no one ever retired on relative returns”. Our long, short, and pair trade ideas are all held to the same standard – positive returns. Since inception, more than 70% of our investment ideas have generated positive absolute returns.
The Research Product
We expect to generate 6-10 investment ideas annually. Clients should expect a relatively equal mix of long, short, and pair trade ideas. Typically the introduction of an investment idea is highlighted by a lengthy report, which includes a comprehensive review of the company’s fundamentals and detail on our investment thesis. We also provide timely updates on each investment idea. Since inception, we have published more than 400 reports on the 35+ ideas we have introduced. Research reports are delivered via email and are also hosted on our website. Research on our website is organized by ticker and industry sector, which enables clients to easily locate the reports they are most interested in.
We do not have a “research coverage” model. Our research product emulates that of the “buy-side”. When catalysts are realized or the investment thesis changes, positions are closed out. We think this keeps the research product fresh and focused.
In addition to published reports, premium and institutional subscribers are able to access the full results of the proprietary surveys we conduct with our industry cont
I've had several of my posts deleted on here. Hope you get to read this before it dissapears. Today's (actually appears in Sunday paper) NY Times article is positive proof. Safalow is advisor to several major hedge funds. Here's his profile: Bradley Safalow founded PAA Research in April 2009 with the goal of bringing the “best of both worlds” from his experience on the buy and sell-side to clients. Mr. Safalow graduated with a bachelor’s degree in economics from the University of Virginia. He started his career in the leveraged finance group at JPMorgan. From 2002-2005, Mr. Safalow was the senior analyst covering the Business and Education Services sector at JPMorgan. After his time at JPMorgan, Mr. Safalow joined RiverEdge Capital, a global long/short equity hedge fund where he focused on small/mid cap stocks and short idea generation. He lives in Marietta, GA with his wife Enders and their sons Clasen and Garrett.
COCO will win the future CA case because COCO now has all data and CA AG has little to no evidence. This case will be dismissed. I read what the judge said today and he said this is a very weak case. Huge news for COCO today. As I said people who sold were idiots. Thanks for the shares.
There are many, many fools shorting this stock and I want to heartily thank them for the shares I was able to buy so cheaply. BTW- All the negative articles are placed by hedge funds that need to cover, and should be totally ignored. Also, Wells never holds a stock under a buck so anyone surprised that they are out is an idiot. Most of the stocks I bought in the past doubled or more in a short time after they filed.